Table 4.

Clinical effects of statins on all-cause mortality in primary prevention: findings from recent meta-analyses

Meta-analysis	Follow-upa	Population	LDL-C		All-cause Mortality
			Baseline	Reduction	No. of deaths/no. of patients	Risk reduction (95% CI)
Thavendiranathan et al41	3.2−5.2 years	N = 42,848 (7 trials)b	147 mg/dL (mean)	−26.1%	N/A	0.92 (0.84−1.01)
		90% without CVD				P = 0.09
Mills et al6	1.0−5.3 yearsc	N = 63,899 (19 trials)b	N/A	N/A	N/A	0.93 (0.87−0.99)
		59.6%–100% without CHD				P = 0.03
Brugts et al42	4.1 years	N = 70,388 (10 trials)	140 mg/dLd (mean)	−25.6%	1725/33,683e	0.88 (0.81−0.96)
		94% without CVD			1925/33,793f
Ray et al39	3.7 years	N = 65,229 (11 trials)	138 mg/dL	−40 mg/dLg	1346/32,623e	0.91 (0.83−1.01)
		100% without CVD			1447/32,606f
Taylor et al40	1.0−5.3 years	N = 34,272 (14 trials)b	153 mg/dLd (median)	−36 mg/dLd,g	794/28,161 (2.8%)	0.83 (0.73−0.95)
		≥ 90% without CVD

Notes:

^aBased on mean and median follow-ups of the individual studies;

^bdid not include JUPITER;

^cvalues shown are follow-up durations or patient characteristics of individual trials included in the meta-analysis;

^dconverted from SI units (mmol/L) using 38.61 as conversion factor;

^estatin group;

^fcontrol group;

^gvs control.

Abbreviations: CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL-C, low-density lipoprotein cholesterol; N/A, not available.